CN1562271A - Medication for treating primary disease of purpura haemorhagica and preparation method - Google Patents
Medication for treating primary disease of purpura haemorhagica and preparation method Download PDFInfo
- Publication number
- CN1562271A CN1562271A CN 200410026011 CN200410026011A CN1562271A CN 1562271 A CN1562271 A CN 1562271A CN 200410026011 CN200410026011 CN 200410026011 CN 200410026011 A CN200410026011 A CN 200410026011A CN 1562271 A CN1562271 A CN 1562271A
- Authority
- CN
- China
- Prior art keywords
- hours
- preparation
- extractum
- medicine
- standby
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating the primary thrombopenic purpura is prepared from 5 Chinese-medicinal materials including natural indigo, forsythia fruit, tree peony bark, liquorice root, etc. Its preparing process is also disclosed.
Description
Technical field:
The present invention relates to a kind of medicine for the treatment of idiopathic thrombocytopenic purpura, is to be the Chinese patent medicine of feedstock production with Chinese medicine specifically, the invention still further relates to the preparation method of this medicine.
Technical background:
Idiopathic thrombocytopenic purpura (ITP) is clinical common acquired autoimmunity hematopathy, and main feature is thrombocytopenia and mucocutaneous hemorrhage.Its annual morbidity is about per 100,000 people 4.8 people morbidity, and child's sickness rate adult is high, sends out the trend that the patient has increase in recent years old age.The Clinical symptoms of ITP is different child and adult, and the former morbidity is more anxious, and symptom is heavier, and is generally better to therapeutic response, and the outbreak of latter's state of an illness is slower, but relatively poor to the reaction of treatment, the part refractory.
Both at home and abroad to the primary disease Drug therapy, run into following problem at present:
(1) though can promote bone marrow initiatively to generate platelet; Be applicable to the thrombocytopenia due to the low proliferative disease of bone marrow; But ITP patient is not had immunoregulation effect, and antagonist generates no effect;
(2), injecting drug use, the patient uses inconvenience;
(3), cost an arm and a leg, clinical practice is limited by economic cause;
(4), biological preparation, allergic phenomena often takes place, edema, headache, heating, cardiopalmus, tachycardia, atrial fibrillation arranged, feel sick, side effect such as vomiting, dizzy, insomnia, dyspnea, erythra.
Summary of the invention:
The object of the present invention is to provide and to prolong platelet life span by regulating the generation that immunologic function reduces platelet-associated antibody, can dwindle spleen again, reduce a kind of medicine for the treatment of idiopathic thrombocytopenic purpura of hematoblastic destruction and detention.
Another object of the present invention provides a kind of preparation method for the treatment of the medicine of idiopathic thrombocytopenic purpura.
For achieving the above object, the technical solution used in the present invention is:
A kind of medicine for the treatment of idiopathic thrombocytopenic purpura, it is by the medicament of following weight proportion raw material:
Indigo Naturalis 20-300 part Cortex Moutan 300-1200 part Fructus Forsythiae 200-800 part
Herba Agrimoniae 200-800 part Radix Glycyrrhizae 50-600 part
The weight proportion of the formula optimization raw material of preparation medicine of the present invention is:
Indigo Naturalis 50-260 part Cortex Moutan 500-1000 part Fructus Forsythiae 300-800 part
Herba Agrimoniae 300-800 part Radix Glycyrrhizae 100-400 part
The weight proportion of the preferable raw material of prescription of preparation medicine of the present invention is:
500 parts of 833 parts of Fructus Forsythiaes of 167 parts of Cortex Moutans of Indigo Naturalis
250 parts in 500 portions of Radix Glycyrrhizaes of Herba Agrimoniae
Above-mentioned medicament is the above dosage form of saying of any pharmaceutics; Can be capsule, granule or tablet medicament.
Above-mentioned dosage form is that the processing step of capsular preparation method is as follows:
(1), the Indigo Naturalis fine powder is sieved, standby;
(2), with Herba Agrimoniae, Cortex Moutan with 5 times of amount 80% ethanol extractions twice, each 2 hours, merge ethanol extract twice, filter, reclaim ethanol and concentrating under reduced pressure and become at 60 ℃, its relative density is the extractum of 1.25-1.30, and is standby;
(3), Fructus Forsythiae was soaked 4 hours, steam distillation extracted volatile oil 6 hours, and volatile oil device is in addition stored, and medicinal residues and decocting liquid are continued to employ;
(4), the medicinal residues and the Radix Glycyrrhizae decocting of step (3) are carried 2 times, decocted 1.5 hours, the decocting liquid in twice decocting liquid and the step (3) merges, and filters, and is condensed at 60 ℃ at every turn, and its relative density is the extractum of 1.25-1.30, and is standby;
(5), the extractum of step (4) with step (2) is merged, the Indigo Naturalis porphyrize powder that adds step (1) preparation, mixing, 60 ℃ of oven dry are ground into fine powder, add an amount of dextrin, ethanol with debita spissitudo is made granule, oven dry, granulate, spray into the volatile oil of step (3), mixing incapsulates, and every capsules is adorned 0.45 gram medicine.
Above-mentioned dosage form is that the processing step of particulate preparation method is as follows:
(1), the Indigo Naturalis fine powder is sieved, standby;
(2), with Herba Agrimoniae, Cortex Moutan with 5 times of amount 80% ethanol extractions twice, each 2 hours, merge ethanol extract twice, filter, reclaim ethanol and concentrating under reduced pressure and become at 60 ℃, its relative density is the extractum of 1.25-1.30, and is standby;
(3), Fructus Forsythiae was soaked 4 hours, steam distillation extracted volatile oil 6 hours, and volatile oil device is in addition stored, and medicinal residues and decocting liquid are continued to employ;
(4), the medicinal residues and the Radix Glycyrrhizae decocting of step (3) are carried 2 times, decocted 1.5 hours, the decocting liquid in twice decocting liquid and the step (3) merges, and filters, and is condensed at 60 ℃ at every turn, and its relative density is the extractum of 1.25-1.30, and is standby;
(5), the extractum of step (4) with step (2) is merged the Indigo Naturalis porphyrize powder of adding step (1) preparation, mixing;
(6), get and mix 1 part of extractum, add 1 part of sucrose, 1 part in dextrin is made granule, drying;
(7), with dried granule 12 orders, 40 orders sieve, after the granule of middle order number mixes, packing, promptly.
Above-mentioned dosage form is that the processing step of preparation method of tablet is as follows
(1), Indigo Naturalis is ground into fine powder, standby;
(2), with Herba Agrimoniae, Cortex Moutan with 5 times of amount 80% ethanol extractions twice, each 2 hours, merge ethanol extract twice, filter, reclaim ethanol and concentrating under reduced pressure and become at 60 ℃, its relative density is the extractum of 1.25-1.30, and is standby;
(3), Fructus Forsythiae was soaked 4 hours, steam distillation extracted volatile oil 6 hours, and volatile oil device is in addition stored, and medicinal residues and decocting liquid are continued to employ;
(4), the medicinal residues and the Radix Glycyrrhizae decocting of step (3) are carried 2 times, decocted 1.5 hours, the decocting liquid in twice decocting liquid and the step (3) merges, and filters, and is condensed at 60 ℃ at every turn, and its relative density is the extractum of 1.25-1.30, and is standby;
(5), with starch: dextrin: Icing Sugar is mixed with excipient in 7: 1.5: 1.5 ratio;
(6), the extractum of step (4) with step (2) is merged the Indigo Naturalis porphyrize powder of adding step (1) preparation, mixing, 60 ℃ of oven dry, be ground into fine powder, add the excipient of step (5) preparation, make granule with the ethanol of suitable concentration, drying sprays into the volatile oil of step (3) gained, mixing;
(7), the granule of step (6) gained is added 0.3% magnesium stearate, tabletting, coating, promptly.
The present invention is with respect to prior art, and its advantage is as follows:
Medicine of the present invention is by being that Indigo Naturalis, Fructus Forsythiae, Herba Agrimoniae, Cortex Moutan, Radix Glycyrrhizae are formed; Experimental results show that this medicine not only has the permeability of certain antibiotic, antiinflammatory, inhibition blood capillary, regulates body's immunity, and tangible rising peripheral blood platelet is arranged, strengthen functions such as platelet aggregation and shortening clotting time, can obviously improve bleeding tendency clinically.
Confirm that through the PRELIMINARY RESULTS to Drug therapy ITP of the present invention produce effects, effective and progressive rate are respectively 51%, 31.1% and 8.9% behind the 90 routine patient treatments, total effective rate is 91.1%.
The specific embodiment:
Medicine main component of the present invention is Indigo Naturalis, Fructus Forsythiae, Herba Agrimoniae, Cortex Moutan, Radix Glycyrrhizae.According to tcm theory, Indigo Naturalis has eliminating pathogen in the liver gallbladder, dissipating blood stasis fire, blood cooling and ecchymoses removing; Cortex Moutan has heat-clearing and toxic substances removing, promoting blood circulation to remove blood stasis; Fructus Forsythiae has heat-clearing and toxic substances removing, dispelling wind eliminating stagnation; Herba Agrimoniae has effects such as astringing to arrest bleeding.Zoopery proves that this medicine not only has the permeability of certain antibiotic, antiinflammatory, inhibition blood capillary, regulates body's immunity, and tangible rising peripheral blood platelet is arranged, strengthen functions such as platelet aggregation and shortening clotting time, can obviously improve bleeding tendency clinically.
In order further to show the clinical efficacy of medicine of the present invention, itemize some clinical observations below, data and case to the treatment idiopathic thrombocytopenic purpura.
Medicine of the present invention is treated 249 routine idiopathic thrombocytopenic purpuras, and sick effect is observed treatment and is reported as follows:
This report is provided by Shaanxi Province's hematopathy study on prevention institute and Rui Jin hospital of Shanghai Second Emdical University;
Idiopathic thrombocytopenic purpura is a kind of commonly encountered diseases, frequently-occurring disease, and cerebral hemorrhage often takes place serious case and the internal organs massive hemorrhage causes death.Doctor trained in Western medicine does not still have the treatment good recipe, uses hormone medicine more, because such medicine has serious adverse, even causes serious patient to infect, multiple fracture etc. and cause death.Most patient's obstinates cause spirit and economic burden greatly, become the intractable hematopathy of attracting attention in the world.ITP is considered to and immune diseases associated, clinical manifestation blood vessel, hemorrhage, the platelet count minimizing of platelet type, and paramophia is produced the platelet megalokaryocyte and is reduced in the bone marrow.We adopt pure Chinese medicinal preparation to treat, and now are reported as follows:
Data and method
This group case is that Shaanxi Province hematopathy study on prevention institute, school Affiliated Hospital are in hospital or the out-patient, and all cases are all learned through clinical, peripheral blood and checked and examination of bone marrow smear is made a definite diagnosis, and select megalokaryocyte to increase type ITP patient as observing case.In 249 examples, male's 156 examples, women's 93 examples; Age reckling 2 years old, the maximum 61 years old; Average course of disease 2.9 years, acute 21 row, the surplus chronic type that all belongs to.100% case is come before the institute all through outer court's diagnosis and treatment, and most cases are all through long periods such as adrenocortical hormone, Chinese medicine no positive effect of treatment or recurrence, or severe haemorrhage or platelet count do not have improvement.90% case all has hemorrhage (as the mucocutaneous hemorrhage point) or the menstruation of varying degree more than when coming, digestive tract hemorrhage person 7 examples, hematuria 1 example.
The thrombocytopenia that varying degree is all arranged before the treatment, platelet＜20 * 10
9/ L person 78 examples,＜40 * 10
9/ L person 86 examples,＜60 * 10
9/ L person 76 examples,＜80 * 10
9/ L person 7 examples,＜100 * 10
9/ L person 2 examples, utmost point anemia 14 examples before the treatment, anemia 11 examples, light, anemia 70 examples amount to 91 examples, and numeration of leukocyte is normal substantially.
Medicine of the present invention is a Chinese medicine preparation, and through consulting ancient literature in conjunction with the modern medicine study achievement, repeated screening is formed prescription, and used high-tech method to make according to traditional Chinese medical science monarch, minister, assistant, history principle.
This group case all adopts medicine of the present invention to treat, must adhere to the course of treatment more than eight weeks, and inactive adrenal cortex hormones drug, must not add the Western medicine that hinders observe the curative effect with other.Extremely heavy anemia case is transfused blood, but none example input platelet.Method of administration is a medicament capsule of the present invention, obeys three every day three times at every turn, and regularly makes the peripheral blood platelet number, does counting three times at every turn, and getting its mean values is the record value.
Interpretation of result: use capsule of the present invention to single, and adhere to treating 249 routine patients more than 8 weeks and observe that clinical symptoms is obviously improved, bleeding alleviates or disappear.148 routine platelet value 〉=1,000,000 * 10 wherein
9/ L was with nothing recurrence in anti-2 years; The no bleeding of 41 examples, before the platelet value is treated 〉=40 * 10
9/ L continues more than 3 months; The no bleeding of 32 examples, platelet be the preceding value added of treatment 〉=30 * 10
9/ L; 10 routine platelet values all increase before the treatment to some extent, but not enough 〉=30 * 10
9/ L, but bleeding significantly improves; 18 examples are through treatment, and characteristic of disease does not have improvement.Cure 148 examples in 249 examples, account for case sum 62.6%, total effective 231 examples account for 92.8%.Varying degree anemia person 91 examples are arranged before the treatment, all reach normal value through the treatment hemoglobin.
This group therapeutic effect and the course of disease do not have significant correlation, with the course of treatment relation show: patient age below 24 years old than more than 24 years old, on average rise digital display work of platelet after treatment.
This organizes effective treatment time, and necessary continuous use is more than 8 weeks, and in the regular hour, the curative effect and the course of treatment are proportionate.
Conclusion: idiopathic thrombocytopenic purpura, be proved to be a kind of autoimmune disease, find to have in patient's body a kind of self platelet antibody that resists.Someone measure ITP patient go into splenic artery blood and go out splenic vein blood in IgG content significantly different, the latter is apparently higher than the former.The splenocyte of corrective surgery excision is cultivated, and IgG concentration significantly raises in the culture fluid, thereby has determined that upright stone tablet is the place that ITP patient produces anti-self platelet antibody.And find that such patient's spleen destroys hematoblastic ability and significantly increases, total number of blood platelet 1/3 storage is stayed among the spleen in the body.Most acute cases all have the medical history of upper respiratory tract infection before sick 1-3 week, see with acute case among the child more.And self limiting is arranged.All recover normal after most case treatments, and the adult sees with chronic type more, and the treatment difficulty.Use heavy dose of adrenocortical hormones in treating and only be adapted to acute, can carry out Splenectomy and treat chronic case, but curative effect is dissatisfied with immunosuppressant.In order to strengthen treatment, improve curative effect, there is the people that ITP is divided into four type acutes, most cases are cured; Recurrent is once cured and also can be shown effect repeatedly, all is the clinical manifestation of acute ITP at every turn; Chronic type, platelet count maintains 40-60
9/ L, no serious hemorrhage performance, but obstinate; The refractory type, promptly through a large amount of adrenocortical hormone, the splenectomy treatment is not prove effective, and immunosuppressant can make the minority case take a turn for the better, and has the people that VLB is mixed in platelet to patient's input, does not also have the curative effect of satisfaction, and it is bigger as above to treat side effect, takes longer.This is organized, and 228 examples account for case sum 91.5% for chronic ITP in 249 examples, and the treatment total effective rate is up to 92.8%.
Contain the medicine of regulating immunity in the medicine of the present invention, invigorate blood circulation, haemostatic medicament and reinforcing drug supporting healthy energy.91 examples have the Secondary cases hemorrhagic anemia in 249 examples, account for 36.5% and treatment back hemoglobin all reaches normal level.Severe haemorrhage person's 79 examples, only 5 examples still have gently to hemorrhage after treatment.Treatment back platelet count is significantly improved, and total effective rate 92.8% is particularly cured up to 62.6%, increases along with following up a case by regular visits to case, and cure rate also can improve constantly, and this has opened up a new treatment approach for chronic ITP.The factor relevant with curative effect seen, age＜24 year old person's curative effect is better, meets with reported literature, and the treatment of this group does not have significant correlation with the course of disease, this is a big feature, chronic case curative effect is relatively poor is generally acknowledged, and this group case no matter how long the course of disease all obtains satisfied curative effect after treating, from statistical information, the medicine for treatment of this group must be adhered to more than 8 weeks, effectively case must be kept treatment 4 months, just can obtain best curative effect, takes without any side effects for a long time.
The clinical observation report of medicament capsule preparation for treating ITP of the present invention is as follows:
1 clinical data and method
1.1 physical data
90 examples all are all in hospital and the ITP patient of outpatient service.All cases meet the diagnostic criteria that second national hematology's academic conference drafted all through clinical and experimental check.Peripheral blood platelet count≤20 * 10
9/ L is the patient with severe symptoms, platelet count 〉=20 * 10
9/ L and to be lower than normal person be middle mild case patient.Patient's general clinical data sees Table 1.Man's 33 examples, women 57 examples, The median age 29 (scope 1.6-67) year.Wherein the adult light in disease ITP patient 38 examples, male 12 examples, women 26 examples, The median age 33.5 examples (scope 18-67) years, first visit 15 examples, recurrence or refractory person 23 examples; Adult serious symptom ITP23 example, male 7 examples, women 16 examples, The median age 26 (scope 17-46) year, first visit 10 examples, recurrence or transfer serious symptom person's 13 examples to by weight disease; Children acute severe group 22 examples, male 11 examples, women 11 examples, The median age 5 (scope 1.6-12) year; Disease was organized 7 examples during the child was light, male 3 examples, women 4 examples, The median age 8 (scope 2-12) year.All patients make regular check on hemogram, bone marrow smear during the treatment, and part patient has also detected the serum platelet-associated antibody (PAIgG) before and after the treatment.
Table 1 patient's physical data
Routine number man/women meta first visit/preceding hemogram of multiple treatment medication * clinical symptoms △ once divides into groups
The age routine Hb WBC Plt that falls ill
Adult serious symptom 23 7,/16 26 10,/13 103 6.7 10.4 Pred (13), VCR (2), hemorrhage (18)
± 21 ± 1.8 ± 5.7 CTX (1), danazol (1)
38 12,/26 33 15,/23 122 6.6 36.4 Pred (17) during the adult is light, VCR (6), hemorrhage (21)
± 16 ± 2.4 ± 12 6TG (1), danazol (17)
Anxious 22 11,/11 5 12,/10 135 10.1 11.9 IVIG (18), Pred (11) hemorrhage (20) of weighing of child
±15 ±2.4 ±4.2
7 3/4 8 4/3 123 7.6 42 Pred (5) hemorrhage (3) during the child is light
±21 ±1.2 ±9.2
Add up to 90 33,/67 30 41/49
represents with mean ± SD, the g/L of unit of Hb, the unit of WBC and Plt * 10
9/ L; * Pred, prednisone; CTX, cyclophosphamide; 6TG, 6 purinethols; IVIG, Gammavenin; VCR, vincristine; Bracket inner digital is the example number.Hemorrhage skin, mucosa and the menorrhagia etc. of being mainly of △, bracket inner digital is the example number.
1.2 Therapeutic Method
For disease person in light, the peripheral blood platelet is 4 * 10
9The above person of/L singly uses medicament capsule preparation of the present invention, and 4, every day 3 times, medication is March at least; Platelet is in (2-4) * 10
9/ L or obvious bleeding tendency person is arranged can add in right amount with short distance prednisone or other symptomatic treatments; For the patient with severe symptoms except taking medicament capsule preparation of the present invention (method is the same), use in conjunction adrenocortical hormone all simultaneously, as prednisone 40-60mg/d, or dexamethasone 2-5mg/d, or methyl meticortelone 80-160mg/d, generally use 2-4 week, or heavy dose of Gammavenin (IVIG, 0.4mg/kg.d * 5) and corresponding suiting the medicine to the illness and Supporting Therapy.
1.3 curative effect assessment
All patients accept 16 weeks treatment back assessment curative effect at least, the criterion evaluation that curative effect is drafted by second national hematology's academic conference (Zhang Zhinan chief editor: hematopathy diagnosis and criterion of therapeutical effect): promptly platelet recovery is normal, and it is produce effects more than 3 months that no bleeding continues; Platelet rises to 5 * 10
9/ L or more former level rise 3 * 10
9More than/the L, do not have or do not have substantially bleeding and continue to imitate for good more than 2 months; Platelet rises to some extent, and it is above for progressive that bleeding improves lasting 2 weeks; The nonresponder then is that platelet count and bleeding do not have improvement or deterioration.
2 results
2.1 medicament capsule preparation for treating 90 routine ITP patients' of the present invention curative effect (seeing Table 2)
All patients' overall produce effects, effective and progressive rate are respectively 51%, 31.1% and 8.9%, and total effective rate is 91.1%.Relatively serious symptom and light in total effective rate between the disease group do not have significant difference, but obvious effective rate no matter in adult and child's severe group all more than 63%, light in disease group (adult and child organize) less than 37% (P＜0.05=then.This may all use in conjunction adrenocortical hormone or IVIG be relevant simultaneously with the former.
The curative effect that table 2 invention medicament capsule is treated 90 routine ITP patients
The routine digital display that divides into groups is imitated routine number and is very imitated the invalid routine number total effective rate of routine number progress example number
(％) (％) (％) (％) (％)
Adult's serious symptom 23 16 (69.6) 3 (13) 1 (4) 3 (13.4) 87.8
During the adult is light 38 14 (36.8) 15 (39.5) 5 (13.2) 4 (10.5) 89.5
The child is anxious to weigh 22 14 (63.6) 5 (22.7) 2 (9.1) 1 (4.5) 95.4
During the child is light 72 (28.6) 5 (71.4)--100
Add up to 90 46 (51.0) 28 (31.1) 8 (8.9) 8 (8.9) 91.1
2.2 treatment back platelet recovery time
By table 3 result as seen, for disease adult patients in light, 4 week of treatment back about half patients' platelet can return to 〉=30 * 10
9/ L, 6 week backs, 68.4% patients rise to 〉=and 50 * 10
9/ L, about 1/3rd rise to normal level after 8 weeks.The patient with severe symptoms is, no matter is adult or child, and treatment back first quarter moon 80% above patient's platelet reaches 30 * 10
9More than/the L, can reach during three weeks 〉=50 * 10
9/ L recovers normal approximately during January more than 70%, and can keep curative effect.
Table 3 is respectively organized the time and the routine number of platelet recovery
Grouping platelet 〉=30 * 0
9/ L platelet 〉=50 * 10
9/ L platelet 〉=100 * 10
9/ L
Example number (%) the treatment numerical example number day after tomorrow (%) the treatment numerical example number day after tomorrow (%) treatment back natural law
Adult's serious symptom 19 (82.6) 17.2 ± 13 20 (87) 22.6 ± 14 16 (69.6) 30.4 ± 17.9
During the adult is light 18 (47.4) 24.9 ± 13 26 (68.4) 36.7 ± 17 14 (36.8) 57.4 ± 22.9
The child is anxious to weigh 21 (95.4) 10.2 ± 7.9 21 (95.4) 13.6 ± 14 18 (81.8) 20.3 ± 22.2
During the child is light 1 (14.3) 76 (85.7)---
Add up to 59 (65.5) 16.5 ± 11.3 73 (81.1) 34.5 ± 15 48 (53.5) 47.5 ± 19
2.3 bone marrow megakaryocyte number and morphologic comparison before and after the treatment
Table 4 illustration bone marrow megakaryocyte number and morphology is relatively before and after the medication, the equal active proliferation of bone marrow before the 90 routine patient treatments, the remarkable hypertrophy of megalokaryocyte, and be accompanied by obvious dysmaturity, 52 examples are checked bone marrow after treating March, average megalokaryocyte digital display work reduces (P＜0.05), and except that minority had slight dysmaturity, it is normal that half has recovered.
Bone marrow megakaryocyte number and morphologic comparison before and after the medication of table 4 some cases
Group example number bone marrow megakaryocyte number/2 * 2cm
2The P value
*Morphological characteristic
Treat preceding 90 289141 obvious dysmaturities
Treatment back 52 13966＜0.5 half is normal, the slight dysmaturity of minority
* with before the treatment compare
2.4 the variation of blood-serum P AIgG before and after the patient treatment
The variation of observing part patients serum PAIgG is as shown in table 5.Treat preceding 37 routine patients and measured PAIgG, wherein 92% patient raises, and treatment back 27 routine review result show that 85% has recovered normal.
The variation of blood-serum P AIgG before and after the table 5 part patient treatment
Group example number blood-serum P AIgG (routine number) P value
*
It is normal to raise
Treat preceding 37 34 3
Treatment back 27 4 23＜0.5
* with before the treatment compare
2.5 toxic and side effects
Behind the oral medicament capsule preparation of the present invention, the routine observation heart, liver, lung, renal function and digestive tract reaction etc. are not found tangible untoward reaction.
3 conclusions
The main feature of ITP is compensatory hypertrophy of platelet destruction, the lost of life, bone marrow megakaryocyte and the corresponding symptoms that immunologic mechanism mechanism causes.Common first-selected adrenocortical hormones in treating, the most of patients short term effect is good.Yet for children acute or adult patient with severe symptoms, its curative effect is not satisfactory, and after decrement or drug withdrawal, curative effect is instability even recurrence often especially.Especially to the treatment of patient with slight symptoms among the adult, certain reaction is arranged in the recent period, need prolonged application though use 17-hydroxy-11-dehydrocorticosterone treatment back, even so, the state of an illness still easily repeatedly, normal protracted course of disease adds with other immunosuppressant (as vincristine, 6-TG etc.) and also is difficult to healing.Can cause many toxic and side effects in order to last medicine for a long time, bring uncomfortable and misery that therefore be necessary further to inquire into new effective more medicine and method, the excavation of Chinese medicine is developed wide prospect to the patient.
This paper has summed up the PRELIMINARY RESULTS of using medicament capsule preparation for treating ITP of the present invention.PRELIMINARY RESULTS confirms that produce effects, effective and progressive rate are respectively 51%, 31.1% and 8.9% behind the 90 routine patient treatments, and total effective rate is 91.1%.Relatively the total effective rate between serious symptom and light middle disease group does not have significant difference, but no matter all remarkable adult and child's severe group obvious effective rate is, light middle disease group (adult and child's group) high (P＜0.05).The patient with severe symptoms treats back first quarter moon 80% above patient's platelet and reaches 30 * 10
9More than/the L, can reach during three weeks 〉=50 * 10
9/ L, the about recovery more than 70% normally during January, and can keep curative effect, this may with severe group all simultaneously use in conjunction adrenocortical hormone or IVIG, therefore its curative effect not only takes place comparatively fast, and obvious effective rate is also higher, and platelet levels does not still obviously descend behind stop using simultaneously hormone and the IVIG, and this continual and steady curative effect may be with to take medicament capsule preparation of the present invention relevant.The disease adult patients is treated the platelet recovery of back about half in 4 weeks to 〉=30 * 10 in light
9/ L, 6 week backs, 68% patients rise to 〉=and 50 * 10
9/ L only 1/3rd rises to normal level after 8 weeks, total effective rate about 90%.It is worth mentioning this class patient, not only effectively and curative effect more stable.Observe part patient medication front and back bone marrow megakaryocyte number and morphological change, find the preceding all active proliferations of bone marrow of treatment, the remarkable hypertrophy of megalokaryocyte, and with obvious dysmaturity, treat 52 example check bone marrow after three months, average megalokaryocyte digital display work reduces (P＜0.05), and except that minority had slight dysmaturity, it is normal that half has recovered.Observe the variation and the preceding PAIgG rising person of prompting treatment of part patients serum PAIgG, effectively the most recoveries in back are normal in treatment.Point out this medicine that being adjusted in the treatment of body's immunity played a major role.Behind the oral invention medicament capsule, routine observation conscience,, lung, renal function and digestive tract reaction etc., do not find tangible untoward reaction.
At present progress of research is thought, in the ITP treatment, remove the cause of disease to mitigate the disease, to keep curative effect very necessary.Wherein autogenous infection is former particularly important with removing focus.Medicine of the present invention is except having the body's immunity of adjusting, the effects such as permeability of certain antibiotic, antiinflammatory, inhibition blood capillary are arranged, so its counterweight, in the curative effect steady in a long-term of light disease relevant with its comprehensive function, clear and definite treatment mechanism and the more clinical control treatment observation of multiple-case, the further further investigation of still needing.
Specific embodiment 1:
Take by weighing raw material by following proportioning:
Indigo Naturalis 167g Cortex Moutan 833g Fructus Forsythiae 500g
Herba Agrimoniae 500g Radix Glycyrrhizae 250g
Described dosage form is that the processing step of capsular preparation method is as follows:
(1), the Indigo Naturalis fine powder is sieved, standby;
(2), with Herba Agrimoniae, Cortex Moutan with 5 times of amount 80% ethanol extractions twice, each 2 hours, merge ethanol extract twice, filter, reclaim ethanol and concentrating under reduced pressure and become at 60 ℃, its relative density is the extractum of 1.25-1.30, and is standby;
(3), Fructus Forsythiae was soaked 4 hours, steam distillation extracted volatile oil 6 hours, and volatile oil device is in addition stored, and medicinal residues and decocting liquid are continued to employ;
(4), the medicinal residues and the Radix Glycyrrhizae decocting of step (3) are carried 2 times, decocted 1.5 hours, the decocting liquid in twice decocting liquid and the step (3) merges, and filters, and is condensed at 60 ℃ at every turn, and its relative density is the extractum of 1.25-1.30, and is standby;
(5), the extractum of step (4) and step (2) is merged, add the Indigo Naturalis porphyrize powder of step (1) preparation, mixing, 60 ℃ of oven dry are ground into fine powder, add an amount of dextrin, make granule, oven dry, granulate with the ethanol of debita spissitudo, spray into the volatile oil of step (3), mixing incapsulates, promptly.
Specific embodiment 2:
Take by weighing raw material by following proportioning:
Indigo Naturalis 150g Cortex Moutan 800g Fructus Forsythiae 600g
Herba Agrimoniae 600g Radix Glycyrrhizae 300g
Described dosage form is that the processing step of particulate preparation method is as follows:
(1), the Indigo Naturalis fine powder is sieved, standby;
(2), with Herba Agrimoniae, Cortex Moutan with 5 times of amount 80% ethanol extractions twice, each 2 hours, merge ethanol extract twice, filter, reclaim ethanol and concentrating under reduced pressure and become at 60 ℃, its relative density is the extractum of 1.25-1.30, and is standby;
(3), Fructus Forsythiae was soaked 4 hours, steam distillation extracted volatile oil 6 hours, and volatile oil device is in addition stored, and medicinal residues and decocting liquid are continued to employ;
(4), the medicinal residues and the Radix Glycyrrhizae decocting of step (3) are carried 2 times, decocted 1.5 hours, the decocting liquid in twice decocting liquid and the step (3) merges, and filters, and is condensed at 60 ℃ at every turn, and its relative density is the extractum of 1.25-1.30, and is standby;
(5), the extractum of step (4) with step (2) is merged the Indigo Naturalis porphyrize powder of adding step (1) preparation, mixing;
(6), get and mix 1 part of extractum, add 1 part of sucrose, 1 part in dextrin is made granule, drying;
(7), with dried granule 12 orders, 40 orders sieve, after the granule of middle order number mixes, packing, promptly.
Specific embodiment 3:
Take by weighing raw material by following proportioning:
Indigo Naturalis 200g Cortex Moutan 700g Fructus Forsythiae 450g
Herba Agrimoniae 450g Radix Glycyrrhizae 350g
Described dosage form is that the processing step of preparation method of tablet is as follows
(1), Indigo Naturalis is ground into fine powder, standby;
(2), with Herba Agrimoniae, Cortex Moutan with 5 times of amount 80% ethanol extractions twice, each 2 hours, merge ethanol extract twice, filter, reclaim ethanol and concentrating under reduced pressure and become at 60 ℃, its relative density is the extractum of 1.25-1.30, and is standby;
(3), Fructus Forsythiae was soaked 4 hours, steam distillation extracted volatile oil 6 hours, and volatile oil device is in addition stored, and medicinal residues and decocting liquid are continued to employ;
(4), the medicinal residues and the Radix Glycyrrhizae decocting of step (3) are carried 2 times, decocted 1.5 hours, the decocting liquid in twice decocting liquid and the step (3) merges, and filters, and is condensed at 60 ℃ at every turn, and its relative density is the extractum of 1.25-1.30, and is standby;
(5), with starch: dextrin: Icing Sugar is mixed with excipient in 7: 1.5: 1.5 ratio;
(6), the extractum of step (4) with step (2) is merged the Indigo Naturalis porphyrize powder of adding step (1) preparation, mixing, 60 ℃ of oven dry, be ground into fine powder, add the excipient of step (5) preparation, make granule with the ethanol of suitable concentration, drying sprays into the volatile oil of step (3) gained, mixing;
(7), the granule of step (6) gained is added 0.3% magnesium stearate, tabletting, coating, promptly.
Claims (8)
1, a kind of medicine for the treatment of idiopathic thrombocytopenic purpura is characterized in that it is a medicament by the following weight proportion raw material:
Indigo Naturalis 20-300 part Cortex Moutan 300-1200 part Fructus Forsythiae 200-800 part
Herba Agrimoniae 200-800 part Radix Glycyrrhizae 50-600 part
2, the medicine of treatment idiopathic thrombocytopenic purpura according to claim 1 is characterized in that: wherein the weight proportion of each raw material is:
Indigo Naturalis 50-260 part Cortex Moutan 500-1000 part Fructus Forsythiae 300-800 part
Herba Agrimoniae 300-800 part Radix Glycyrrhizae 100-400 part
3, the medicine of treatment idiopathic thrombocytopenic purpura according to claim 1 is characterized in that: wherein the weight proportion of each raw material is:
500 parts of 833 parts of Fructus Forsythiaes of 167 parts of Cortex Moutans of Indigo Naturalis
250 parts in 500 portions of Radix Glycyrrhizaes of Herba Agrimoniae
4, according to the medicine of claim 1 or 2 or 3 described treatment idiopathic thrombocytopenic purpuras, it is characterized in that: described medicament is the above dosage form of saying of any pharmaceutics.
5, the medicine of treatment idiopathic thrombocytopenic purpura according to claim 4 is characterized in that: described medicament is capsule, granule or tablet.
6, the preparation method of the medicine of treatment idiopathic thrombocytopenic purpura according to claim 5 is characterized in that:
Described dosage form is that the processing step of capsular preparation method is as follows:
(1), the Indigo Naturalis fine powder is sieved, standby;
(2), with Herba Agrimoniae, Cortex Moutan with 5 times of amount 80% ethanol extractions twice, each 2 hours, merge ethanol extract twice, filter, reclaim ethanol and concentrating under reduced pressure and become at 60 ℃, its relative density is the extractum of 1.25-1.30, and is standby;
(3), Fructus Forsythiae was soaked 4 hours, steam distillation extracted volatile oil 6 hours, and volatile oil device is in addition stored, and medicinal residues and decocting liquid are continued to employ;
(4), the medicinal residues and the Radix Glycyrrhizae decocting of step (3) are carried 2 times, decocted 1.5 hours, the decocting liquid in twice decocting liquid and the step (3) merges, and filters, and is condensed at 60 ℃ at every turn, and its relative density is the extractum of 1.25-1.30, and is standby;
(5), the extractum of step (4) and step (2) is merged, add the Indigo Naturalis porphyrize powder of step (1) preparation, mixing, 60 ℃ of oven dry are ground into fine powder, add an amount of dextrin, make granule, oven dry, granulate with the ethanol of debita spissitudo, spray into the volatile oil of step (3), mixing incapsulates, promptly.
7, the preparation method of the medicine of treatment idiopathic thrombocytopenic purpura according to claim 5 is characterized in that:
Described dosage form is that the processing step of particulate preparation method is as follows:
(1), the Indigo Naturalis fine powder is sieved, standby;
(2), with Herba Agrimoniae, Cortex Moutan with 5 times of amount 80% ethanol extractions twice, each 2 hours, merge ethanol extract twice, filter, reclaim ethanol and concentrating under reduced pressure and become at 60 ℃, its relative density is the extractum of 1.25-1.30, and is standby;
(3), Fructus Forsythiae was soaked 4 hours, steam distillation extracted volatile oil 6 hours, and volatile oil device is in addition stored, and medicinal residues and decocting liquid are continued to employ;
(4), the medicinal residues and the Radix Glycyrrhizae decocting of step (3) are carried 2 times, decocted 1.5 hours, the decocting liquid in twice decocting liquid and the step (3) merges, and filters, and is condensed at 60 ℃ at every turn, and its relative density is the extractum of 1.25-1.30, and is standby;
(5), the extractum of step (4) with step (2) is merged the Indigo Naturalis porphyrize powder of adding step (1) preparation, mixing;
(6), get and mix 1 part of extractum, add 1 part of sucrose, 1 part in dextrin is made granule, drying;
(7), with dried granule 12 orders, 40 orders sieve, after the granule of middle order number mixes, packing, promptly.
8, the preparation method of the medicine of treatment idiopathic thrombocytopenic purpura according to claim 5 is characterized in that:
Described dosage form is that the processing step of preparation method of tablet is as follows
(1), Indigo Naturalis is ground into fine powder, standby;
(2), with Herba Agrimoniae, Cortex Moutan with 5 times of amount 80% ethanol extractions twice, each 2 hours, merge ethanol extract twice, filter, reclaim ethanol and concentrating under reduced pressure and become at 60 ℃, its relative density is the extractum of 1.25-1.30, and is standby;
(3), Fructus Forsythiae was soaked 4 hours, steam distillation extracted volatile oil 6 hours, and volatile oil device is in addition stored, and medicinal residues and decocting liquid are continued to employ;
(4), the medicinal residues and the Radix Glycyrrhizae decocting of step (3) are carried 2 times, decocted 1.5 hours, the decocting liquid in twice decocting liquid and the step (3) merges, and filters, and is condensed at 60 ℃ at every turn, and its relative density is the extractum of 1.25-1.30, and is standby;
(5), with starch: dextrin: Icing Sugar is mixed with excipient in 7: 1.5: 1.5 ratio;
(6), the extractum of step (4) with step (2) is merged the Indigo Naturalis porphyrize powder of adding step (1) preparation, mixing, 60 ℃ of oven dry, be ground into fine powder, add the excipient of step (5) preparation, make granule with the ethanol of suitable concentration, drying sprays into the volatile oil of step (3) gained, mixing;
(7), the granule of step (6) gained is added 0.3% magnesium stearate, tabletting, coating, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100260113A CN1293896C (en) | 2004-04-05 | 2004-04-05 | Medication for treating primary disease of purpura haemorhagica and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100260113A CN1293896C (en) | 2004-04-05 | 2004-04-05 | Medication for treating primary disease of purpura haemorhagica and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562271A true CN1562271A (en) | 2005-01-12 |
| CN1293896C CN1293896C (en) | 2007-01-10 |
Family
ID=34480534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100260113A Ceased CN1293896C (en) | 2004-04-05 | 2004-04-05 | Medication for treating primary disease of purpura haemorhagica and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1293896C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288703B (en) * | 2008-05-21 | 2011-03-02 | 迟静 | Trotter-7 soup for treating essential thrombocytopenia |
| CN102920836A (en) * | 2012-11-28 | 2013-02-13 | 徐昌万 | Traditional Chinese medicine composite for treating immune thrombocytopenic purpura |
| CN105267761A (en) * | 2015-12-02 | 2016-01-27 | 张秀萍 | Traditional Chinese medicine for treating chronic idiopathic thrombocytopenic purpura and preparation method thereof |
| CN105288283A (en) * | 2015-11-06 | 2016-02-03 | 孙殿亮 | Traditional Chinese medicine for treating idiopathic thrombocytopenic purpura and preparation method thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006831B (en) * | 2013-01-17 | 2013-07-31 | 陕西郝其军制药股份有限公司 | Blood platelet raising capsules, namely Chinese herbal combination, and preparation method of capsules |
| CN103006832B (en) * | 2013-01-17 | 2013-07-31 | 陕西郝其军制药股份有限公司 | Chinese herbal combination for raising blood platelets and preparation method of combination |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1164285C (en) * | 2001-01-16 | 2004-09-01 | 麻福伟 | Medicine for treating primary thrombocytopenia purpura |
| CN1130214C (en) * | 2001-02-27 | 2003-12-10 | 丁丛礼 | Medicine for treating purpura caused by lupus erythematosus and other immunological disease |
| CN1270757C (en) * | 2002-07-12 | 2006-08-23 | 刘光跃 | Chinese traditional medicine for treating purpuric disease and method for making the same |
-
2004
- 2004-04-05 CN CNB2004100260113A patent/CN1293896C/en not_active Ceased
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288703B (en) * | 2008-05-21 | 2011-03-02 | 迟静 | Trotter-7 soup for treating essential thrombocytopenia |
| CN102920836A (en) * | 2012-11-28 | 2013-02-13 | 徐昌万 | Traditional Chinese medicine composite for treating immune thrombocytopenic purpura |
| CN102920836B (en) * | 2012-11-28 | 2014-05-07 | 徐昌万 | Traditional Chinese medicine composite for treating immune thrombocytopenic purpura |
| CN105288283A (en) * | 2015-11-06 | 2016-02-03 | 孙殿亮 | Traditional Chinese medicine for treating idiopathic thrombocytopenic purpura and preparation method thereof |
| CN105267761A (en) * | 2015-12-02 | 2016-01-27 | 张秀萍 | Traditional Chinese medicine for treating chronic idiopathic thrombocytopenic purpura and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1293896C (en) | 2007-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1861163A (en) | Traditional Chinese medicine composition for treating kidney-yang deficiency and deficiency of vital energy and blood, its prepn. process | |
| CN1686458A (en) | Chinese medicinal composition, its preparation method and use | |
| CN1915399A (en) | Preparation for treating high blood pressure, high blood fat, obesity, and climacteric syndrome, and preparation method | |
| CN1561994A (en) | Medicinal compositon containing artemisine extract for treating rheumatoid arthritis and immunologic disease | |
| CN1052163C (en) | Chinese patent medicine for curing gallstones and kidney stones | |
| CN1293896C (en) | Medication for treating primary disease of purpura haemorhagica and preparation method | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1304735A (en) | Medicine for curing chronic colitis | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1872273A (en) | Medication composition for treating cardiovascular diseases and cerebrovascular disease, and preparation method | |
| CN1686202A (en) | Bone pain dispersing granular composition and its preparation method | |
| CN1679658A (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN101032540A (en) | Medicine composition for curing arthritis and the preparing method and purpose thereof | |
| CN102552724B (en) | Chinese medicine composite for curing hypertension | |
| CN1045892C (en) | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof | |
| CN1232283C (en) | Chinese drugs for treatment of coronary heart disease and angina pectoris | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN1593439A (en) | Orally disintegrating tablet of notoginsen total saponins and its preparation | |
| CN1515274A (en) | Medicine for curing coronary heart disease | |
| CN1569095A (en) | Medicine for treating cerebral infarction | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1250278C (en) | Oral medicine for treating dementia and feeblemindedpess | |
| CN1958061A (en) | Technique for preparing Chinese traditional medicine and pills in use for clearing away heart-fire, dispersing phlegm, tranquilizing the mind, and reducing pressure | |
| CN1413653A (en) | Chinese drugs for treating cardiovascular and cerebrovascular system disease and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C35 | Partial or whole invalidation of patent or utility model | ||
| IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20100312 Decision number of declaring invalidation: 14545 Granted publication date: 20070110 |